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Response to ‘Angiotensin-
converting enzyme 2 (ACE2)
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We thank Dr Amao1 for the interest in our study of ACE2
expression in kidney biopsies of human subjects with
diabetic nephropathy (DN), and other forms of glomerular
disease.2 Indeed, we did not study ACE2 gene or protein
expression in biopsies of diabetic subjects without
DN and, as mentioned in our discussion, it is not known
whether the same observation would occur in such
individuals. The feasibility of this type of study is
questionable, given that it would be difficult to justify
kidney biopsy in human subjects without clinical evidence
of renal disease. Similarly, it is not known whether ACE2
expression in diabetic patients could be used to predict the
development of DN. We also agree that the reported
differences in ACE2 expression in different animal models
of DN and human studies could relate to disease stage.
Appreciation of the complexity of the renin–angiotensin
system and its intrinsic balances continues to grow. We
agree with Dr Amao that the potential influence of direct
renin inhibition on the protective effects of ACE2 merits
further study.
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High-volume peritoneal dialysis in
acute kidney injury
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To the Editor: In a study comparing high-volume peritoneal
dialysis (HVPD) and daily hemodialysis (DHD), Gabriel
et al.1 report their experience from a randomized controlled
trial. The authors report a mortality of 58% for HVPD and
53% for DHD. Subsequently, the article mentions 24
survivors in HVPD and 29 survivors in DHD, each group
comprising 60 patients. Taking the figures of survivors into
account, the mortality for the HVPD group should have been
reported as 60% and that for the DHD group as 51.66% (or
as 52%, the nearest whole number).
The study also compares the efficacy of HVPD in
metabolic control with that of DHD. However, they excluded
patients with severe hypercatabolism according to Schrier’s
criteria2 at the time of randomization, giving the impression
that the authors accepted the limitations of HVPD before-
hand. Chitalia et al.3 have earlier reported peritoneal dialysis
to be reasonably effective in mild and moderate hyper-
catabolic acute renal failure. It would have been interesting to
observe the efficacy of HVPD in severely hypercatabolic
patients, especially when the authors have used very high
volumes of 36–44 l/day of dialysis fluid for 7 days a week with
a target Kt/V of 0.65/day.
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We appreciate the interest of Dr Palya and colleagues1 in
our paper.2 We agree that further exploration of the
relationship between progestin use, either with or without
estrogen, and loss of kidney function would be of great
interest. The importance of the type of progestin contained
in hormonal preparations has been previously high-
lighted.3,4 Studies have suggested a link between adverse
cardiac, vascular, and thrombotic events depending on the
type of progestin exposure,3,4 and indicate that the type of
progestin in a hormonal preparation may play a role in
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attenuating the vascular effects of estrogen.3,5 As outlined
in our study limitations, there are diverse metabolic and
clinical effects of different types of both estrogens and
progestins, and our study was not powered to analyze the
renal consequences for each of the individual synthetic
hormone preparations.
Although diuretic use did vary by categorical hormone
therapy use, inclusion of this variable in the model
did not change the relationship between hormone therapy
use and loss of kidney function we have previously
reported;2 as such this variable was not included in our
final models.
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